StockBox

Investor Perspective on Physiomics & Market Opportunities

The interview centers on Mike Whitlo’s activist stance toward Physomics, a natural‑resources‑focused firm whose board he now challenges. Whitlo, a private‑equity investor with a 12% holding, explains that he rotated capital from prior successful resource plays into Physomics, only to encounter a hostile board that he says is sabotaging shareholder value. He argues the company’s market price reflects a corporate‑governance problem, not operational weakness. Whitlo points to an 80‑90% share‑price decline driven by dilution—share counts have ballooned tenfold over a decade—while the business continues to trade at roughly one‑times revenue. He accuses the chairman of pursuing costly fund‑raises that disadvantage investors and labels the board’s recent public statements as “malicious” and “prematurely disruptive.” Whitlo’s rebuttal outlines concrete steps: he will step aside if an orderly handover occurs, has identified two seasoned candidates for non‑executive oversight, and urges the current chairman to resign. He stresses that the valuation gap is a short‑term blip and that, once governance is corrected, the upside could be substantial. If Whitlo’s demands succeed, Physomics could see a governance reset, a clearer capital‑allocation strategy, and a potential rebound in share price, offering a renewed entry point for investors who have been waiting for the market to stabilize after a three‑year slump.